World's Best Scientists 2026 revealed!
Madhav V. Dhodapkar

Madhav V. Dhodapkar

D-Index & Metrics

Immunology

D-Index
89
Citations
34573
World Ranking
1104
National Ranking
589

Medicine

D-Index
89
Citations
34601
World Ranking
12548
National Ranking
6423

Madhav V. Dhodapkar publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Madhav V. Dhodapkar sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 406 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Madhav V. Dhodapkar D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Madhav V. Dhodapkar sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 89 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Madhav V. Dhodapkar is affiliated with Emory University in the United States. Their research primarily focuses on the field of Medicine, with significant contributions to subfields including Hematology, Oncology, Molecular Biology, Immunology, and Infectious Diseases.

The scientist's work extensively covers topics related to Multiple Myeloma Research and Treatments, CAR-T cell therapy research, Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses, Cancer Treatment and Pharmacology, and SARS-CoV-2 and COVID-19 Research.

The publication record includes a range of peer-reviewed papers such as:

  • Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma, 2020, Journal of Clinical Oncology
  • Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial, 2020, The Lancet Haematology
  • Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma, 2022, Blood Cancer Discovery
  • Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression, 2021, Blood
  • Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma, 2024, Journal of Clinical Oncology

Their frequent co-authors include:

  • Sagar Lonial
  • Ajay K. Nooka
  • Jonathan L. Kaufman
  • Nisha S. Joseph
  • Craig C. Hofmeister

Madhav V. Dhodapkar has published extensively in several academic venues. The most common publication outlets are:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Blood Cancer Discovery
  • bioRxiv (Cold Spring Harbor Laboratory)

Best Publications

  • Antitumor activity of thalidomide in refractory multiple myeloma.

    S Singhal;J Mehta;R Desikan;D Ayers

  • Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.

    Madhav V. Dhodapkar;Ralph M. Steinman;Joseph Krasovsky;Christian Munz

  • Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris

    Edmund Jd Lee;William L. Trepicchio;Judith L Oestreicher;Debra D Pittman

  • Immune and Clinical Responses in Patients with Metastatic Melanoma to CD34+ Progenitor-derived Dendritic Cell Vaccine

    Jacques Banchereau;A. Karolina Palucka;Madhav Dhodapkar;Susan Burkeholder

  • Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study

    Alexander M. Lesokhin;Alexander M. Lesokhin;Stephen M. Ansell;Philippe Armand;Emma C. Scott

  • Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

    Benjamin Besse;Mélinda Charrier;Valérie Lapierre;Eric Dansin

  • A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.

    Madhav V. Dhodapkar;Madhav V. Dhodapkar;Matthew D. Geller;David H. Chang;Kanako Shimizu

  • Dendritic cell function in vivo during the steady state: a role in peripheral tolerance.

    Ralph M. Steinman;Daniel Hawiger;Kang Liu;Laura Bonifaz

  • Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients

    David H. Chang;Keren Osman;John Connolly;Anjli Kukreja

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells

    M V Dhodapkar;R M Steinman;M Sapp;H Desai

  • Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells

    Kavita M. Dhodapkar;Joseph Krasovsky;Barbara Williamson;Madhav V. Dhodapkar;Madhav V. Dhodapkar

  • Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.

    Radek Spisek;Anna Charalambous;Amitabha Mazumder;David H. Vesole

  • Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.

    Madhav V. Dhodapkar;Ralph M. Steinman

  • Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

    Rituparna Das;Rakesh Verma;Mario Sznol;Chandra Sekhar Boddupalli

  • International prognostic scoring system for Waldenstrom macroglobulinemia

    Pierre Morel;Alain Duhamel;Paolo Gobbi;Meletios A. Dimopoulos

  • Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients

    Devi K. Banerjee;Madhav V. Dhodapkar;Elyana Matayeva;Ralph M. Steinman

  • Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

    Fenghuang Zhan;Bart Barlogie;Varant Arzoumanian;Yongsheng Huang

  • Active immunization against cancer with dendritic cells: the near future.

    Ralph M. Steinman;Madhav Dhodapkar;Madhav Dhodapkar

  • Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

    Robert A. Kyle;Steven P. Treon;Raymond Alexanian;Bart Barlogie

Frequent Co-Authors

Sagar Lonial
Sagar Lonial Emory University
Bart Barlogie
Bart Barlogie Mount Sinai Hospital
Lawrence H. Boise
Lawrence H. Boise Emory University
John Crowley
John Crowley Washington University in St. Louis
Vikas Gupta
Vikas Gupta Princess Margaret Cancer Centre
Richard A. Flavell
Richard A. Flavell Yale University
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center
Frits van Rhee
Frits van Rhee University of Arkansas for Medical Sciences
Ralph M. Steinman
Ralph M. Steinman Rockefeller University
Till Strowig
Till Strowig Helmholtz Centre for Infection Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related healthcare degrees can expand career opportunities. Many students pivot toward nursing roles that complement their immunology knowledge, such as becoming a Licensed Practical Nurse (LPN) or a Nurse Practitioner (NP). Programs with easy admission LPN programs provide an accessible pathway to begin a healthcare career with less stringent entry requirements.

If you're considering advanced practice, several of the easiest NP programs to get into offer manageable admission criteria while still preparing graduates for rewarding roles in patient care and immunology-related specialties.

Mental health nursing often intersects with immunology through inflammatory and neurological conditions. Students interested in psychiatric nursing can benefit from PMHNP programs online with best clinical placement, which ensure hands-on experience through strong affiliations with healthcare facilities.

For those concerned about budget, exploring cheapest PMHNP certificate programs can make advanced psychiatric nursing education more accessible, helping students pursue specialized roles without overwhelming financial burden.

Best Scientists Citing Madhav V. Dhodapkar

Trending Scientists

Recently Published Articles